Use of Clinical Global Impressions‐Severity (CGI‐S) to assess response to antidepressant treatment in patients with treatment‐resistant depression
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: This post-hoc analysis evaluated the agreement between Clinical Global Impressions-Severity (CGI-S) score- and Montgomery-Åsberg Depression Rating Scale (MADRS) total score-based assessment of response in patients with treatment-resistant depression (TRD) treated with esketamine nasal spray plus a newly initiated oral antidepressant (ESK-NS + AD). Methods: Data were analyzed from a phase 3, randomized, double-blind study (TRANSFORM-2) of flexibly dosed esketamine or placebo nasal spray plus a newly initiated oral-AD in adults with moderate-to-severe TRD. Patients with ≥50% reduction in MADRS from baseline at the end of the 4-week acute treatment phase were defined as responders. For the CGI-S-based assessment of response, patients with ≥2 points decrease from baseline or a CGI-S score of ≤3 (mildly depressed to normal) were considered responders. Cohen's kappa coefficient was calculated to assess level of agreement between MADRS and CGI-S-based assessments. Results: At the end of 4-week treatment, the proportion of responders among all study patients (n=201) was similar when assessed using the MADRS (61%) and CGI-S (62%) methods, with substantial agreement (Cohen's kappa=0.76; sensitivity=92%; specificity=84%) between both methods. When restricting analysis to ESK-NS + AD-treated patients (n=101) who had a higher response rate (on MADRS: 69%; on CGI-S: 68%), the agreement remained substantial (Cohen's kappa=0.75; sensitivity=91%; specificity=84%). Conclusion: The CGI-S may be a practical and reliable alternative to the MADRS to assess response to ESK-NS + AD in patients with TRD and can be used in real-world practice to support informed treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 5×
“tionnaire (each item yields a score of 0 to 6), is a validated, clinician-rated measure of depression designed to measure depression severity and to detect changes due to antidepressant treatment in patients with MDD.(6) It is one of the most”
BackgroundMethodInfluentialThe clinical global impressions scale: applying a research tool in clinical practice.
Busner, J., & Targum, S. D. (2007) · PubMed · Cited by 2,759
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 3×
“This post-hoc analysis was based on data from over 200 adult patients with the same diagnosis (and definition) of TRD participating in a phase 3 clinical study from the registration program of esketamine nasal spray, representing a relatively homogenous population for assessment.(17) Furthermore, the analysis included…”
MethodInfluentialSelf-citationDaly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Using Measurement-Based Care to Enhance Any Treatment
Scott, K., & Lewis, C. C. (2015) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2014.01.010 · Cited by 461 · cited 1×
“Introduction Measurement-based care (MBC) is a critical component of an evidence-based decision support framework that guides patient treatment.(1) In mental health clinical practice, MBC approaches have been designed to provide systematic,”
BackgroundWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
A Comparison of Depression Rating Scales
Kearns, N. P., Cruickshank, C. A., McGuigan, K. J., Riley, S. A., Shaw, S. P., & Snaith, R. P. (1982) · British Journal of Psychiatry · doi:10.1192/bjp.141.1.45 · Cited by 271 · cited 1×
“a research instrument usually takes approximately 20–40 minutes to administer and therefore may not be feasible for clinicians to use in their routine practice.(6,8) By contrast, the Clinical Global Impressions-Severity (CGI-S) is a single-item, 7-point scale designed to assess global impression of severity rather tha…”
MethodMeasurement-Based Care in Psychiatric Practice: A Policy Framework for Implementation
Harding, K. J. K., Rush, A. J., Arbuckle, M., Trivedi, M. H., & Pincus, H. A. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06282whi · Cited by 175 · cited 1×
“Given the variety of rating scales, using clinically and practically relevant measures that could potentially lower the burden of time associated with assessment is of great importance.(19,20) The MADRS has been used in pivotal clinical studies of antidepressants; however, its adoption in clinical practice is uncommon.”
MethodKhan, A., Khan, S. R., Shankles, E. B., & Polissar, N. L. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00003 · Cited by 162 · cited 2×
“frequently used scales for assessment of depression in clinical trials of antidepressant treatments submitted to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).(5,7) However, the MADRS as”
MethodQuilty, L. C., Robinson, J. J., Rolland, J., Fruyt, F. D., Rouillon, F., & Bagby, R. M. (2013) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1388 · Cited by 136 · cited 1×
“The CGI-S directly reflects a clinician’s judgment and captures clinical impressions of depression severity based on observed and reported symptoms, behavior, and function in the past 7 days.(9,10) The scale has also shown good inter-rater reliability among clinicians.”
MethodTrivedi, M. H., & Daly, E. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.01.007 · Cited by 115 · cited 1×
“quantitative assessments to track treatment progress, measure symptom severity and reflect on important aspects of health-related quality of life, satisfaction and functioning.(2,3) Thus, MBC can be implemented in various ways to enhance”
BackgroundTurkoz, I., Alphs, L., Singh, J., Jamieson, C., Daly, E., Shawi, M., Sheehan, J. J., Trivedi, M. H., & Rush, A. J. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13260 · Cited by 104 · cited 2×
“In a recent post-hoc analysis of phase 3 studies of esketamine nasal spray in patients with treatmentresistant depression (TRD), a 2-point reduction in CGI-S score corresponded to a 12-point reduction in MADRS, thus establishing thresholds for clinically meaningful within-patient changes and better interpretability.(1…”
MethodSelf-citationLeucht, S., Fennema, H., Engel, R. R., Kaspers–Janssen, M., Lepping, P., & Szegedi, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.12.041 · Cited by 96 · cited 6×
“A 1-point reduction in CGI-S score translated into an 8–9-point change in MADRS total score, in a study evaluating the relationship of MADRS and CGI-S scales in patients with MDD.7 Another study concluded that based on a 1-point improvement in the CGI-S anchor, a 10-point improvement on the MADRS is an appropriate mea…”
BackgroundMethodInfluentialConway, C. R., Kumar, A., Xiong, W., Bunker, M., Aaronson, S. T., & Rush, A. J. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.18m12178 · Cited by 92
Hudgens, S., Floden, L., Blackowicz, M., Jamieson, C., Popova, V., Fedgchin, M., Drevets, W. C., Cooper, K., Lane, R., & Singh, J. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.066 · Cited by 80 · cited 1×
“Another study concluded that based on a 1-point improvement in the CGI-S anchor, a 10-point improvement on the MADRS is an appropriate meaningful change threshold for withinpatient change.(12) In a recent post-hoc analysis of phase 3 studies of esketamine nasal spray in patients with treatmentresistant depression (TRD…”
MethodSelf-citationDefinition of Treatment-Resistant Depression in the Medicare Population
Bradley N. Gaynes, M. D., Gary Asher, M. D., Gerald Gartlehner, M. D., Valerie Hoffman, P. D., Josh Green, B. A., Erin Boland, M. S. P. H., Linda Lux, M. P. A., Charlotte Randolph, B. A., Carla Bann, P. D., Emmanuel Cokker-Schwimmer, M. P. H., et al. (2018) · Systematic Review Data Repository · doi:10.26300/4j7h-jk02 · Cited by 58
Hong, R. H., Murphy, J. K., Michalak, E. E., Chakrabarty, T., Wang, Z., Parikh, S., Culpepper, L., Yatham, L. N., Lam, R. W., & Chen, J. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s283731 · Cited by 55
Measurement-Based Care in Psychiatry
Waldrop, J., & McGuinness, T. M. (2017) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20170818-01 · Cited by 43 · cited 1×
“Given the variety of rating scales, using clinically and practically relevant measures that could potentially lower the burden of time associated with assessment is of great importance.(19,20) The MADRS has been used in pivotal clinical studies of antidepressants; however, its adoption in clinical practice is uncommon.”
MethodJiang, Q., & Ahmed, S. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-4 · Cited by 31 · cited 5×
“naires for assessments of symptoms have been used to measure treatment outcomes in clinical studies of patients with major depressive disorder (MDD).(4,5) The Montgomery–Åsberg Depression Rating Scale (MADRS), a 10-item ques-”
BackgroundMethodInfluentialAdaptation of the Clinical Global Impression for Use in Correctional Settings: The CGI-C
Jones, R. M., Patel, K., Moscovici, M., McMaster, R., Glancy, G., & Simpson, A. I. F. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00687 · Cited by 15
Barbero (2014) · doi:10.1016/j · Cited by 1
Research works printed but not linked: 2
- Busner, 2007, Psychiatry, 4, 28
- 1976, ECDEU Assessment Manual for Psychopharmacology
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Lipton, R. B., Campos, V. R., Arie, Z. R.-B., Galić, M., Mitsikostas, D. D., Tassorelli, C., Denysenko, L., & Cohen, J. M. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0806 · Cited by 35
Espinosa, V., Valiente, R. M., García-Escalera, J., Chorot, P., Arnáez, S., Schmitt, J. C., & Sandín, B. (2024) · Behaviour Research and Therapy · doi:10.1016/j.brat.2024.104560 · Cited by 16
Gutiérrez, G., Kang, M. J. Y., & Vázquez, G. H. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115865 · Cited by 18
“All data generated or analyzed during this study is available as needed upon reasonable request.”
Method
Metadata
- Authors
- Morrens, J., Mathews, M., Popova, V., Borentain, S., Rive, B., Gonzalez Martin Moro, B., Jamieson, C., & Zhang, Q.
- Affiliations
- Janssen (Belgium) (BE)
- Janssen Research & Development (United States) (US)
- Corresponding author
- Zhang, Qiaoyi
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2022-06
- Volume
- Volume 18
- Pages
- 1127-1132
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC9189368
- OpenAlex
- W4281790437
- Cited by
- 24
- References
- 22
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 2
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- treatment-resistant depression, esketamine nasal spray, Montgomery-Asberg Depression Rating Scale, flexible dosing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.